Key clinical point: Use of lipid-lowering drugs was associated with a significantly lower risk of dying from colorectal cancer, both overall and in different subgroups.
Major finding: Compared with patients who never used lipid-lowering medications, those who did use these medications had a significantly lower risk of colorectal cancer–related death (hazard ratio, 0.44).
Study details: An analysis of 14,428 patients in the Atherosclerosis Risk in Communities study who were cancer free at study visits between 1990 and 1992.
Disclosures: This research was funded by grants from the National Cancer Institute; the National Heart, Lung, and Blood Institute; the National Program of Cancer Registries; and the American Association for Cancer Research. Dr. Marrone disclosed no conflicts of interest.
Marrone MT et al. AACR 2020, Abstract 2357.